Management of bone metastases

Cancer Treatment Reviews

Volumn 23, Issue SUPPL. 1, 1997, Pages

  Coleman, Robert ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID;

BONE METABOLISM; BONE METASTASIS; CLINICAL TRIAL; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; ORAL DRUG ADMINISTRATION; OSTEOCLAST; OSTEOLYSIS; REVIEW;

EID: 0030724586     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(97)90009-8     Document Type: Article

References (17)

1. Scher, H. I. & Yagoda, A. (1987) Bone metastases: pathogenesis, treatment and rationale for use of resorption inhibitors. Am. J. Med. 82(Suppl 2a): 6-27.
2. Rubens, R. D. & Coleman, R. E. (1995) Bone metastases. In: Abeloff, M. D., Armitage, J. O., Lichter, A. S. & Niederhuber, J. E. Clinical Oncology. New York, NY (USA): Churchill Livingstone, 643-665.
3. Coleman, R. E. (1994) Evaluation of bone disease in breast cancer. Breast 3: 73-78.
4. Lipton, A., Demers, L., Seyedin, S., et al. (1993) Increased urinary excretion of pyridinium cross-links in cancer patients. Clin. Chem. 39: 614-618.
5. Pecherstorfer, M., Ludwig, H., Seibel, M., et al. (1995) The diagnostic value of urinary pyridinium cross-links of collagen, alkaline phosphatase and urinary calcium excretion in neoplastic bone disease. J. Clin. End. Met. 80: 97-103.
6. Myamoto, K. K., McSherry, S. A., Robins, S. A., et al. (1994) Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. J. Urol. 151: 909-913.
7. Body, J.-J., Coleman, R. E. & Piccart, M. (1996) Use of bisphosphonates in cancer patients. Cancer Treat Rev 22: 265-287.
8. Purohit, O. P., Anthony, C., Coleman, R. E., et al. (1994) High-dose intravenous pamidronate for metastatic bone pain. Br. J. Cancer 70: 554-855.
9. Robertson, A. G., Reed, N. S. & Ralston, S. H. (1995) Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J. Clin. Oncol. 13: 2427-2430.
10. Lahtinen, R., Laasko, M., Elomaa, I., et al. for the Finnish Leukaemia Group. (1992) Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340: 1049-1052.
11. Paterson, A. H. G., Powles, T. J., Kanis, J. A., et al. (1993) Double blind controlled trial of clodronate in patients with bone metastase from breast cancer. J. Clin. Oncol. 11: 59-65.
12. Berenson, J., Lichtenstein, A., Knight, R., et al. for the Myeloma Aredia Study Group. (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N. Eng. J. Med. 334: 488-493.
13. Hortobagyi, G. N., Porter, L., Reitsma, D. J., et al. (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic metastases. N. Eng. J. Med. 335: 1785-1791.
14. Conte, P. F., Giannessi, P. G., Mauriac, L., et al. (1996) Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomised controlled trial. J. Clin. Oncol. 14: 2552-2559.
15. Lipton, A., Theriault, R., Left, R., et al. (1997) Long-term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly 90 mg pamidronate (Aredia) infusions. ASCO Proc 16: 152a.
16. Vinholes, J., Eastell, R., Coleman, R., et al. (1996) Metabolic effects of pamidronate in patients with metastatic bone disease. Br. J. Cancer 73: 1089-1095.
17. Coleman, R. E., Purohit, O. P., Vinholes, J.J. & Zekri, J. (1997) High dose pamidronate - Clinical and biochemical effects in metastatic bone disease. Cancer (In press)